JP2017530196A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017530196A5 JP2017530196A5 JP2017538156A JP2017538156A JP2017530196A5 JP 2017530196 A5 JP2017530196 A5 JP 2017530196A5 JP 2017538156 A JP2017538156 A JP 2017538156A JP 2017538156 A JP2017538156 A JP 2017538156A JP 2017530196 A5 JP2017530196 A5 JP 2017530196A5
- Authority
- JP
- Japan
- Prior art keywords
- liquid pharmaceutical
- pharmaceutical formulation
- pharmaceutical preparation
- preparation according
- polysaccharides
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000126 substance Substances 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims 74
- 239000008194 pharmaceutical composition Substances 0.000 claims 41
- 239000000825 pharmaceutical preparation Substances 0.000 claims 33
- 150000004676 glycans Chemical class 0.000 claims 12
- 229920001282 polysaccharide Polymers 0.000 claims 12
- 239000005017 polysaccharide Substances 0.000 claims 12
- 108020004707 nucleic acids Proteins 0.000 claims 11
- 102000039446 nucleic acids Human genes 0.000 claims 11
- 150000007523 nucleic acids Chemical class 0.000 claims 11
- 238000002347 injection Methods 0.000 claims 9
- 239000007924 injection Substances 0.000 claims 9
- 239000002904 solvent Substances 0.000 claims 7
- 239000003638 chemical reducing agent Substances 0.000 claims 5
- 239000000203 mixture Substances 0.000 claims 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims 3
- 238000010255 intramuscular injection Methods 0.000 claims 3
- 239000007927 intramuscular injection Substances 0.000 claims 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims 3
- 238000010254 subcutaneous injection Methods 0.000 claims 3
- 239000007929 subcutaneous injection Substances 0.000 claims 3
- 108020004414 DNA Proteins 0.000 claims 2
- 102000053602 DNA Human genes 0.000 claims 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims 2
- 238000007918 intramuscular administration Methods 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 238000007920 subcutaneous administration Methods 0.000 claims 2
- 150000005846 sugar alcohols Chemical class 0.000 claims 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 claims 1
- 102000053642 Catalytic RNA Human genes 0.000 claims 1
- 108090000994 Catalytic RNA Proteins 0.000 claims 1
- 229920001661 Chitosan Polymers 0.000 claims 1
- 229920001287 Chondroitin sulfate Polymers 0.000 claims 1
- 108020004638 Circular DNA Proteins 0.000 claims 1
- 229920002558 Curdlan Polymers 0.000 claims 1
- 239000001879 Curdlan Substances 0.000 claims 1
- 229920000858 Cyclodextrin Polymers 0.000 claims 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims 1
- 108091008102 DNA aptamers Proteins 0.000 claims 1
- 108091027757 Deoxyribozyme Proteins 0.000 claims 1
- 229920000045 Dermatan sulfate Polymers 0.000 claims 1
- 229920002971 Heparan sulfate Polymers 0.000 claims 1
- 229920000288 Keratan sulfate Polymers 0.000 claims 1
- 108091007460 Long intergenic noncoding RNA Proteins 0.000 claims 1
- 229930195725 Mannitol Natural products 0.000 claims 1
- 108091030071 RNAI Proteins 0.000 claims 1
- 108020004682 Single-Stranded DNA Proteins 0.000 claims 1
- 108091027967 Small hairpin RNA Proteins 0.000 claims 1
- 108020004459 Small interfering RNA Proteins 0.000 claims 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims 1
- 229940072056 alginate Drugs 0.000 claims 1
- 229920000615 alginic acid Polymers 0.000 claims 1
- 235000010443 alginic acid Nutrition 0.000 claims 1
- 239000003963 antioxidant agent Substances 0.000 claims 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims 1
- 239000006172 buffering agent Substances 0.000 claims 1
- 239000004067 bulking agent Substances 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 239000002738 chelating agent Substances 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 229940094517 chondroitin 4-sulfate Drugs 0.000 claims 1
- KXKPYJOVDUMHGS-OSRGNVMNSA-N chondroitin sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](OS(O)(=O)=O)[C@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](C(O)=O)O1 KXKPYJOVDUMHGS-OSRGNVMNSA-N 0.000 claims 1
- 239000002577 cryoprotective agent Substances 0.000 claims 1
- 235000019316 curdlan Nutrition 0.000 claims 1
- 229940078035 curdlan Drugs 0.000 claims 1
- AVJBPWGFOQAPRH-FWMKGIEWSA-L dermatan sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@H](OS([O-])(=O)=O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](C([O-])=O)O1 AVJBPWGFOQAPRH-FWMKGIEWSA-L 0.000 claims 1
- 229940051593 dermatan sulfate Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 238000011156 evaluation Methods 0.000 claims 1
- 230000009368 gene silencing by RNA Effects 0.000 claims 1
- 229920000669 heparin Polymers 0.000 claims 1
- 229960002897 heparin Drugs 0.000 claims 1
- 239000002628 heparin derivative Substances 0.000 claims 1
- 229920002674 hyaluronan Polymers 0.000 claims 1
- 229960003160 hyaluronic acid Drugs 0.000 claims 1
- 230000007794 irritation Effects 0.000 claims 1
- KXCLCNHUUKTANI-RBIYJLQWSA-N keratan Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@H](COS(O)(=O)=O)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@H](O[C@@H](O[C@H]3[C@H]([C@@H](COS(O)(=O)=O)O[C@@H](O)[C@@H]3O)O)[C@H](NC(C)=O)[C@H]2O)COS(O)(=O)=O)O[C@H](COS(O)(=O)=O)[C@@H]1O KXCLCNHUUKTANI-RBIYJLQWSA-N 0.000 claims 1
- 239000000594 mannitol Substances 0.000 claims 1
- 235000010355 mannitol Nutrition 0.000 claims 1
- 108020004999 messenger RNA Proteins 0.000 claims 1
- 108091070501 miRNA Proteins 0.000 claims 1
- 239000002679 microRNA Substances 0.000 claims 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims 1
- 229920005615 natural polymer Polymers 0.000 claims 1
- 229920001983 poloxamer Polymers 0.000 claims 1
- 229920001223 polyethylene glycol Polymers 0.000 claims 1
- 229920005862 polyol Polymers 0.000 claims 1
- 150000003077 polyols Chemical class 0.000 claims 1
- 229940031937 polysaccharide vaccine Drugs 0.000 claims 1
- 229950008882 polysorbate Drugs 0.000 claims 1
- 229920000136 polysorbate Polymers 0.000 claims 1
- 229920002451 polyvinyl alcohol Polymers 0.000 claims 1
- 229940071643 prefilled syringe Drugs 0.000 claims 1
- 239000003755 preservative agent Substances 0.000 claims 1
- 108091092562 ribozyme Proteins 0.000 claims 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- 239000002924 silencing RNA Substances 0.000 claims 1
- 239000004055 small Interfering RNA Substances 0.000 claims 1
- 239000000600 sorbitol Substances 0.000 claims 1
- 230000006641 stabilisation Effects 0.000 claims 1
- 238000011105 stabilization Methods 0.000 claims 1
- 239000004094 surface-active agent Substances 0.000 claims 1
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 2
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 229960003495 thiamine Drugs 0.000 description 2
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 2
- 235000019157 thiamine Nutrition 0.000 description 2
- 239000011721 thiamine Substances 0.000 description 2
- RKUNBYITZUJHSG-FXUDXRNXSA-N (S)-atropine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@H]3CC[C@@H](C2)N3C)=CC=CC=C1 RKUNBYITZUJHSG-FXUDXRNXSA-N 0.000 description 1
- WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 description 1
- LEBVLXFERQHONN-UHFFFAOYSA-N 1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide Chemical compound CCCCN1CCCCC1C(=O)NC1=C(C)C=CC=C1C LEBVLXFERQHONN-UHFFFAOYSA-N 0.000 description 1
- RICAYURMNZSWDK-UHFFFAOYSA-N 3-(2-methylimidazol-1-yl)propan-1-amine;dihydrochloride Chemical compound Cl.Cl.CC1=NC=CN1CCCN RICAYURMNZSWDK-UHFFFAOYSA-N 0.000 description 1
- 229930000680 A04AD01 - Scopolamine Natural products 0.000 description 1
- 229930003347 Atropine Natural products 0.000 description 1
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 1
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 1
- YQKAVWCGQQXBGW-UHFFFAOYSA-N Piperocaine Chemical compound CC1CCCCN1CCCOC(=O)C1=CC=CC=C1 YQKAVWCGQQXBGW-UHFFFAOYSA-N 0.000 description 1
- -1 Rebechiraseta arm Chemical compound 0.000 description 1
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 1
- 229960000396 atropine Drugs 0.000 description 1
- BTNNPSLJPBRMLZ-LGMDPLHJSA-N benfotiamine Chemical compound C=1C=CC=CC=1C(=O)SC(/CCOP(O)(O)=O)=C(/C)N(C=O)CC1=CN=C(C)N=C1N BTNNPSLJPBRMLZ-LGMDPLHJSA-N 0.000 description 1
- 229960002873 benfotiamine Drugs 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 229960003150 bupivacaine Drugs 0.000 description 1
- 229960003677 chloroquine Drugs 0.000 description 1
- WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 description 1
- CCGSUNCLSOWKJO-UHFFFAOYSA-N cimetidine Chemical compound N#CNC(=N/C)\NCCSCC1=NC=N[C]1C CCGSUNCLSOWKJO-UHFFFAOYSA-N 0.000 description 1
- 229960001380 cimetidine Drugs 0.000 description 1
- 229960001747 cinchocaine Drugs 0.000 description 1
- PUFQVTATUTYEAL-UHFFFAOYSA-N cinchocaine Chemical compound C1=CC=CC2=NC(OCCCC)=CC(C(=O)NCCN(CC)CC)=C21 PUFQVTATUTYEAL-UHFFFAOYSA-N 0.000 description 1
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 description 1
- 229960002227 clindamycin Drugs 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 125000004981 cycloalkylmethyl group Chemical group 0.000 description 1
- JTLXCMOFVBXEKD-FOWTUZBSSA-N fursultiamine Chemical compound C1CCOC1CSSC(\CCO)=C(/C)N(C=O)CC1=CN=C(C)N=C1N JTLXCMOFVBXEKD-FOWTUZBSSA-N 0.000 description 1
- 229950006836 fursultiamine Drugs 0.000 description 1
- MFWNKCLOYSRHCJ-BTTYYORXSA-N granisetron Chemical compound C1=CC=C2C(C(=O)N[C@H]3C[C@H]4CCC[C@@H](C3)N4C)=NN(C)C2=C1 MFWNKCLOYSRHCJ-BTTYYORXSA-N 0.000 description 1
- 229960003727 granisetron Drugs 0.000 description 1
- 229930005342 hyoscyamine Natural products 0.000 description 1
- 229960003210 hyoscyamine Drugs 0.000 description 1
- OEXHQOGQTVQTAT-JRNQLAHRSA-N ipratropium Chemical class O([C@H]1C[C@H]2CC[C@@H](C1)[N@@+]2(C)C(C)C)C(=O)C(CO)C1=CC=CC=C1 OEXHQOGQTVQTAT-JRNQLAHRSA-N 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- INWLQCZOYSRPNW-UHFFFAOYSA-N mepivacaine Chemical compound CN1CCCCC1C(=O)NC1=C(C)C=CC=C1C INWLQCZOYSRPNW-UHFFFAOYSA-N 0.000 description 1
- 229960002409 mepivacaine Drugs 0.000 description 1
- FABPRXSRWADJSP-MEDUHNTESA-N moxifloxacin Chemical compound COC1=C(N2C[C@H]3NCCC[C@H]3C2)C(F)=CC(C(C(C(O)=O)=C2)=O)=C1N2C1CC1 FABPRXSRWADJSP-MEDUHNTESA-N 0.000 description 1
- 229960003702 moxifloxacin Drugs 0.000 description 1
- UDCIYVVYDCXLSX-SDNWHVSQSA-N n-[(4-amino-2-methylpyrimidin-5-yl)methyl]-n-[(e)-5-hydroxy-3-(propyldisulfanyl)pent-2-en-2-yl]formamide Chemical compound CCCSS\C(CCO)=C(/C)N(C=O)CC1=CN=C(C)N=C1N UDCIYVVYDCXLSX-SDNWHVSQSA-N 0.000 description 1
- 229960001045 piperocaine Drugs 0.000 description 1
- 229950007142 prosultiamine Drugs 0.000 description 1
- UKHVLWKBNNSRRR-TYYBGVCCSA-M quaternium-15 Chemical compound [Cl-].C1N(C2)CN3CN2C[N+]1(C/C=C/Cl)C3 UKHVLWKBNNSRRR-TYYBGVCCSA-M 0.000 description 1
- 229940096792 quaternium-15 Drugs 0.000 description 1
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 1
- 229960002646 scopolamine Drugs 0.000 description 1
- CKHJPWQVLKHBIH-ZDSKVHJSSA-N sulbutiamine Chemical compound C=1N=C(C)N=C(N)C=1CN(C=O)C(/C)=C(/CCOC(=O)C(C)C)SS\C(CCOC(=O)C(C)C)=C(\C)N(C=O)CC1=CN=C(C)N=C1N CKHJPWQVLKHBIH-ZDSKVHJSSA-N 0.000 description 1
- 229960003211 sulbutiamine Drugs 0.000 description 1
- LERNTVKEWCAPOY-DZZGSBJMSA-N tiotropium Chemical compound O([C@H]1C[C@@H]2[N+]([C@H](C1)[C@@H]1[C@H]2O1)(C)C)C(=O)C(O)(C=1SC=CC=1)C1=CC=CS1 LERNTVKEWCAPOY-DZZGSBJMSA-N 0.000 description 1
- 229940110309 tiotropium Drugs 0.000 description 1
- 229930004006 tropane Natural products 0.000 description 1
- XLRPYZSEQKXZAA-OCAPTIKFSA-N tropane Chemical compound C1CC[C@H]2CC[C@@H]1N2C XLRPYZSEQKXZAA-OCAPTIKFSA-N 0.000 description 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462058122P | 2014-10-01 | 2014-10-01 | |
| US201462058124P | 2014-10-01 | 2014-10-01 | |
| US201462058125P | 2014-10-01 | 2014-10-01 | |
| US201462058123P | 2014-10-01 | 2014-10-01 | |
| US62/058,124 | 2014-10-01 | ||
| US62/058,123 | 2014-10-01 | ||
| US62/058,122 | 2014-10-01 | ||
| US62/058,125 | 2014-10-01 | ||
| PCT/US2015/053313 WO2016054259A1 (en) | 2014-10-01 | 2015-09-30 | Polysaccharide and nucleic acid formulations containing viscosity-lowering agents |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017530196A JP2017530196A (ja) | 2017-10-12 |
| JP2017530196A5 true JP2017530196A5 (https=) | 2018-11-08 |
| JP6716577B2 JP6716577B2 (ja) | 2020-07-01 |
Family
ID=55631454
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017538156A Active JP6716577B2 (ja) | 2014-10-01 | 2015-09-30 | 粘度低下物質を含有する、多糖および核酸の調合薬 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US11471479B2 (https=) |
| EP (1) | EP3200804A4 (https=) |
| JP (1) | JP6716577B2 (https=) |
| KR (1) | KR102497368B1 (https=) |
| CN (1) | CN106999510B (https=) |
| AU (1) | AU2015325055B2 (https=) |
| CA (1) | CA2962768C (https=) |
| IL (1) | IL251390B (https=) |
| MX (1) | MX391067B (https=) |
| SG (2) | SG10201902915VA (https=) |
| WO (1) | WO2016054259A1 (https=) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL312865B2 (en) * | 2013-09-11 | 2025-06-01 | Eagle Biologics Inc | Liquid protein formulations containing viscosity-lowering agents |
| US11357857B2 (en) | 2014-06-20 | 2022-06-14 | Comera Life Sciences, Inc. | Excipient compounds for protein processing |
| US10478498B2 (en) | 2014-06-20 | 2019-11-19 | Reform Biologics, Llc | Excipient compounds for biopolymer formulations |
| WO2015196091A1 (en) | 2014-06-20 | 2015-12-23 | Reform Biologics, Llc | Viscosity-reducing excipient compounds for protein formulations |
| RU2612014C1 (ru) * | 2015-10-19 | 2017-03-01 | Общество с ограниченной ответственностью "ДИАМЕД-фарма" | Средство для лечения артрологических заболеваний |
| JP2020507593A (ja) * | 2017-02-16 | 2020-03-12 | リフォーム バイオロジクス、エルエルシー | タンパク質処理用賦形剤化合物 |
| CA3063324A1 (en) | 2017-05-16 | 2018-11-22 | Bhami's Research Laboratory, Pvt. Ltd. | High concentration protein formulations with reduced viscosity |
| KR102101384B1 (ko) * | 2017-11-02 | 2020-04-16 | 연세대학교 산학협력단 | 허혈성 심혈관 질환의 치료용 또는 예방용 약학 조성물 |
| CN111918644A (zh) * | 2017-11-17 | 2020-11-10 | 哈佛大学校长及研究员协会 | 用于内部递送的离子液体 |
| KR102056144B1 (ko) * | 2018-03-08 | 2019-12-16 | 주식회사 파마리서치프로덕트 | Dna 단편 혼합물이 고농도로 함유된 유동성을 갖는 액제 조성물 및 이의 제조방법 |
| WO2019222726A1 (en) | 2018-05-18 | 2019-11-21 | The General Hospital Corporation | Compound for improving l-arginine bioavailability |
| EP3930757A1 (en) | 2019-03-01 | 2022-01-05 | President And Fellows Of Harvard College | Methods and compositions for protein delivery |
| US11365405B2 (en) | 2019-03-20 | 2022-06-21 | Anchor Molecular Inc. | Method of removing nucleic acids from human plasma |
| WO2020212628A1 (es) * | 2019-04-18 | 2020-10-22 | Fundació Institut De Ciències Fotòniques | Aparato fluídico para interrogación óptica de microorganismos individuales |
| WO2021097228A1 (en) * | 2019-11-13 | 2021-05-20 | The General Hospital Corporation | Compositions and salts for improving l-arginine bioavailability |
| US11684594B2 (en) | 2020-05-12 | 2023-06-27 | President And Fellows Of Harvard College | Antifungal prophylaxis for cornea |
| CN112458001B (zh) * | 2020-07-30 | 2022-09-27 | 上海交通大学 | 一种可降解多环芳烃的菌株及其应用 |
| EP4429704A4 (en) | 2021-11-10 | 2025-11-05 | I2O Therapeutics Inc | IONIC LIQUID COMPOSITIONS |
| US12193972B2 (en) | 2022-07-22 | 2025-01-14 | SpyGlass Pharma, Inc. | Intraocular drug delivery systems and methods of use |
| WO2024028218A1 (en) * | 2022-08-01 | 2024-02-08 | Merck Patent Gmbh | Viscosity reducing excipients and combinations thereof for highly concentrated nucleic acid compositions |
| CN120187311A (zh) * | 2022-10-26 | 2025-06-20 | 帝斯曼知识产权资产管理有限公司 | 包含糖类和氨基酸的制剂和组合物及其用途 |
Family Cites Families (162)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB750373A (en) | 1953-01-15 | 1956-06-13 | Pfizer & Co C | Improvements in or relating to injectable suspension of penicillin salts |
| DK128416B (da) | 1964-08-13 | 1974-04-29 | Ciba Geigy Ag | Analogifremgangsmåde til fremstilling af adrenocorticotropt aktive nonadecapeptidamider eller syreadditionssalte eller kompleksforbindelser deraf. |
| BE757195A (fr) | 1969-10-07 | 1971-03-16 | Century Disposable Devices | Seringue servant a injecter un melange fraichement prepare de poudre etde liquide |
| JPS5270014A (en) | 1975-12-05 | 1977-06-10 | Senju Pharma Co | Stabilization of pyrido*3*22a*phenoxadine compounds |
| US4171698A (en) | 1977-08-15 | 1979-10-23 | Abbott Laboratories | Prefilled two-compartment syringe |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
| US5034506A (en) | 1985-03-15 | 1991-07-23 | Anti-Gene Development Group | Uncharged morpholino-based polymers having achiral intersubunit linkages |
| US5506337A (en) | 1985-03-15 | 1996-04-09 | Antivirals Inc. | Morpholino-subunit combinatorial library and method |
| JP3022967B2 (ja) | 1985-03-15 | 2000-03-21 | アンチバイラルズ インコーポレイテッド | 立体規則性ポリヌクレオチド結合ポリマー |
| US5217866A (en) | 1985-03-15 | 1993-06-08 | Anti-Gene Development Group | Polynucleotide assay reagent and method |
| US5166315A (en) | 1989-12-20 | 1992-11-24 | Anti-Gene Development Group | Sequence-specific binding polymers for duplex nucleic acids |
| US5521063A (en) | 1985-03-15 | 1996-05-28 | Antivirals Inc. | Polynucleotide reagent containing chiral subunits and methods of use |
| AU4128089A (en) | 1988-09-15 | 1990-03-22 | Rorer International (Overseas) Inc. | Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same |
| US5001000A (en) | 1988-09-26 | 1991-03-19 | E. I. Du Pont De Nemours And Company | Process for forming a composite structure of thermoplastic polymer and sheet molding compound |
| US5114703A (en) * | 1989-05-30 | 1992-05-19 | Alliance Pharmaceutical Corp. | Percutaneous lymphography using particulate fluorocarbon emulsions |
| US5730978A (en) | 1989-09-01 | 1998-03-24 | Fred Hutchinson Cancer Research Center | Inhibition of lymphocyte adherence with α4β1-specific antibodies |
| US6033665A (en) | 1989-09-27 | 2000-03-07 | Elan Pharmaceuticals, Inc. | Compositions and methods for modulating leukocyte adhesion to brain endothelial cells |
| JPH03190823A (ja) | 1989-12-21 | 1991-08-20 | Snow Brand Milk Prod Co Ltd | エリスロポエチン皮下又は筋肉投与剤 |
| US5698195A (en) | 1991-03-18 | 1997-12-16 | New York University Medical Center | Methods of treating rheumatoid arthritis using chimeric anti-TNF antibodies |
| US5539082A (en) | 1993-04-26 | 1996-07-23 | Nielsen; Peter E. | Peptide nucleic acids |
| US5714331A (en) | 1991-05-24 | 1998-02-03 | Buchardt, Deceased; Ole | Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| US5356802A (en) | 1992-04-03 | 1994-10-18 | The Johns Hopkins University | Functional domains in flavobacterium okeanokoites (FokI) restriction endonuclease |
| US5436150A (en) | 1992-04-03 | 1995-07-25 | The Johns Hopkins University | Functional domains in flavobacterium okeanokoities (foki) restriction endonuclease |
| US5487994A (en) | 1992-04-03 | 1996-01-30 | The Johns Hopkins University | Insertion and deletion mutants of FokI restriction endonuclease |
| US5736137A (en) | 1992-11-13 | 1998-04-07 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
| DK0678122T3 (da) | 1993-01-12 | 2000-03-06 | Biogen Inc | Rekombinante anti-VLA4 antistofmolekyler |
| US5334162A (en) | 1993-03-15 | 1994-08-02 | Eli Lilly And Company | Cartridge assembly for a lyophilized compound forming a disposable portion of an injector pen and method for same |
| US5744155A (en) * | 1993-08-13 | 1998-04-28 | Friedman; Doron | Bioadhesive emulsion preparations for enhanced drug delivery |
| US5527675A (en) | 1993-08-20 | 1996-06-18 | Millipore Corporation | Method for degradation and sequencing of polymers which sequentially eliminate terminal residues |
| DE4331012A1 (de) | 1993-09-13 | 1995-03-16 | Bayer Ag | Nukleinsäuren-bindende Oligomere mit N-Verzweigung für Therapie und Diagnostik |
| DE4344824C1 (de) | 1993-12-28 | 1995-08-31 | Immuno Ag | Hochkonzentriertes Immunglobulin-Präparat und Verfahren zu seiner Herstellung |
| US5840299A (en) | 1994-01-25 | 1998-11-24 | Athena Neurosciences, Inc. | Humanized antibodies against leukocyte adhesion molecule VLA-4 |
| GB9418092D0 (en) | 1994-09-08 | 1994-10-26 | Red Cross Found Cent Lab Blood | Organic compounds |
| JP3524974B2 (ja) | 1994-12-26 | 2004-05-10 | ブラッコ インターナショナル ビーヴィ | プレフィルドシリンジおよびその包装体 |
| US5569193A (en) | 1995-03-22 | 1996-10-29 | Abbott Laboratories | Syringe system accommodating separately storable prefilled containers for two constituents |
| US5779668A (en) | 1995-03-29 | 1998-07-14 | Abbott Laboratories | Syringe barrel for lyophilization, reconstitution and administration |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| US6685940B2 (en) | 1995-07-27 | 2004-02-03 | Genentech, Inc. | Protein formulation |
| DE19617369A1 (de) | 1996-04-30 | 1997-11-06 | Immuno Ag | Lagerstabile Fibrinogen-Präparate |
| US6184037B1 (en) | 1996-05-17 | 2001-02-06 | Genemedicine, Inc. | Chitosan related compositions and methods for delivery of nucleic acids and oligonucleotides into a cell |
| GB9610992D0 (en) | 1996-05-24 | 1996-07-31 | Glaxo Group Ltd | Concentrated antibody preparation |
| US5819998A (en) | 1996-09-30 | 1998-10-13 | Everything Kids | Knapsack with simulated basketball court |
| IN184589B (https=) | 1996-10-16 | 2000-09-09 | Alza Corp | |
| US6065645A (en) | 1997-04-01 | 2000-05-23 | Discus Dental Impressions, Inc. | Double-barreled syringe with detachable locking mixing tip |
| US5819988A (en) | 1997-04-01 | 1998-10-13 | Sawhney; Ravi K. | Double-barreled syringe with detachable locking mixing tip |
| US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
| US5786571A (en) | 1997-05-09 | 1998-07-28 | Lexmark International, Inc. | Wrapped temperature sensing assembly |
| US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
| KR100373480B1 (ko) | 1997-10-15 | 2003-02-25 | 아사히 가세이 가부시키가이샤 | 트롬보모듈린 수용액 주사제의 저장 및 유통시의 품질유지 방법 |
| AU752461B2 (en) | 1997-10-22 | 2002-09-19 | Chugai Seiyaku Kabushiki Kaisha | Method of screening TGF-beta inhibitory substances |
| US7919109B2 (en) | 1999-02-08 | 2011-04-05 | Intarcia Therapeutics, Inc. | Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles |
| FR2794649B1 (fr) * | 1999-06-11 | 2003-04-11 | Solutions | Biomateriau a base d'un derive de dextrane insolubilise et d'un facteur de croissance, son procede de preparation et ses applications |
| AUPQ132599A0 (en) * | 1999-07-01 | 1999-07-22 | Commonwealth Scientific And Industrial Research Organisation | Nasogastric enteral formulations |
| US7030097B1 (en) * | 1999-07-14 | 2006-04-18 | Cornell Research Foundation, Inc. | Controlled nucleic acid delivery systems |
| EP1072323B1 (de) | 1999-07-29 | 2003-09-10 | Wilhelm A. Keller | Kartuschen-Austraggerät mit Antrieb für dynamischen Mischer |
| DE60031999T2 (de) | 1999-10-04 | 2007-06-06 | Novartis Vaccines and Diagnostics, Inc., Emeryville | Stabilisierte flüssige polypeptid-haltige pharmazeutische zusammensetzungen |
| US6394314B1 (en) | 1999-10-12 | 2002-05-28 | Discus Dental Impressions, Inc. | Double-barreled syringe with detachable locking mixing tip |
| US6443612B1 (en) | 1999-12-02 | 2002-09-03 | Wilhelm A. Keller | Dynamic mixer |
| AU2002213441B2 (en) | 2000-10-12 | 2006-10-26 | Genentech, Inc. | Reduced-viscosity concentrated protein formulations |
| US8703126B2 (en) | 2000-10-12 | 2014-04-22 | Genentech, Inc. | Reduced-viscosity concentrated protein formulations |
| KR20030071780A (ko) | 2000-11-30 | 2003-09-06 | 바이오밸브 테크놀로지스, 인코포레이티드 | 주입기 |
| US20040259247A1 (en) | 2000-12-01 | 2004-12-23 | Thomas Tuschl | Rna interference mediating small rna molecules |
| EP1392827A4 (en) | 2001-05-16 | 2005-12-21 | Biomarin Pharm Inc | DESTRUCTION OF PRIONS BY VIBRIOLYSIN OR VARIANTS THEREOF |
| GB0113179D0 (en) | 2001-05-31 | 2001-07-25 | Novartis Ag | Organic compounds |
| CA2454587C (en) | 2001-07-25 | 2012-11-13 | Protein Design Labs, Inc. | Stable lyophilized pharmaceutical formulation of igg antibodies |
| US7501001B2 (en) | 2001-08-02 | 2009-03-10 | 3M Innovative Properties Company | Abrasive particles, and methods of making and using the same |
| JP4167820B2 (ja) | 2001-10-19 | 2008-10-22 | アルインコ株式会社 | デッキプレート走行台車 |
| GB0212405D0 (en) | 2002-05-29 | 2002-07-10 | Insignion Holdings Ltd | Composition and its therapeutic use |
| US9415102B2 (en) | 2002-09-06 | 2016-08-16 | Alexion Pharmaceuticals, Inc. | High concentration formulations of anti-C5 antibodies |
| AU2003293543A1 (en) | 2002-12-13 | 2004-07-09 | Abgenix, Inc. | System and method for stabilizing antibodies with histidine |
| ES2532399T3 (es) | 2003-03-05 | 2015-03-26 | Halozyme, Inc. | Glicoproteína hialuronidasa soluble (sHASEGP), proceso para prepararla, usos y composiciones farmacéuticas que la comprenden |
| DE602004015755D1 (de) | 2003-03-31 | 2008-09-25 | Alza Corp | Nicht wässrige einphasige visköse vehikel und formulierungen die diese vehikel verwenden |
| US20050158303A1 (en) | 2003-04-04 | 2005-07-21 | Genentech, Inc. | Methods of treating IgE-mediated disorders comprising the administration of high concentration anti-IgE antibody formulations |
| CN1798575A (zh) | 2003-04-04 | 2006-07-05 | 健泰科生物技术公司 | 高浓度抗体和蛋白制剂 |
| US7341843B2 (en) | 2003-04-11 | 2008-03-11 | Allergan, Inc. | Botulinum toxin A peptides and methods of predicting and reducing immunoresistance to botulinum toxin therapy |
| CA2522544A1 (en) | 2003-04-15 | 2004-10-28 | Ista Pharmaceuticals, Inc. | Process for isolating and purifing ovine hyaluronidase |
| WO2004103342A2 (en) | 2003-05-16 | 2004-12-02 | Alkermes Controlled Therapeutics, Inc. | Injectable sustained release compositions |
| US20070184084A1 (en) * | 2003-05-30 | 2007-08-09 | Guohua Chen | Implantable elastomeric caprolactone depot compositions and uses thereof |
| EP2364725A3 (en) * | 2003-06-23 | 2012-05-09 | Sanofi Pasteur Inc. | Immunization method against neisseria meningitidis serogroups a and c |
| CN1206344C (zh) | 2003-07-28 | 2005-06-15 | 中国海洋大学 | 一种用细菌生产岩藻聚糖硫酸酯酶的方法 |
| GB0327723D0 (en) * | 2003-09-15 | 2003-12-31 | Vectura Ltd | Pharmaceutical compositions |
| JP2007523050A (ja) | 2003-09-17 | 2007-08-16 | カイアズマ・リミテッド | 生物学的障壁を通した透過を容易にすることのできる組成物 |
| EP1532983A1 (en) | 2003-11-18 | 2005-05-25 | ZLB Bioplasma AG | Immunoglobulin preparations having increased stability |
| GB0403938D0 (en) * | 2004-02-21 | 2004-03-24 | West Pharm Serv Drug Res Ltd | Chitosan containing solution |
| ES2346212T3 (es) | 2004-11-25 | 2010-10-13 | Chr. Hansen A/S | Metodo para la preparacion de una laca de acido carminico. |
| US20060142234A1 (en) | 2004-12-23 | 2006-06-29 | Guohua Chen | Injectable non-aqueous suspension |
| US20060141040A1 (en) | 2004-12-23 | 2006-06-29 | Guohua Chen | Injectable non-aqueous suspension |
| CA2867194C (en) | 2005-10-07 | 2016-10-04 | The University Of Alabama | Multi-functional ionic liquid compositions for overcoming polymorphism and imparting improved properties for active pharmaceutical, biological, nutritional, and energetic ingredients |
| CN100416002C (zh) | 2005-10-26 | 2008-09-03 | 曲新华 | 污水再生利用装置 |
| CN101584858A (zh) | 2005-12-20 | 2009-11-25 | 布里斯托尔-迈尔斯斯奎布公司 | 稳定蛋白质制剂 |
| US9309316B2 (en) | 2005-12-20 | 2016-04-12 | Bristol-Myers Squibb Company | Stable subcutaneous protein formulations and uses thereof |
| BRPI0620316A2 (pt) | 2005-12-21 | 2011-11-08 | Wyeth Corp | formulações de proteìnas com viscosidades reduzida e seus usos |
| US9084777B2 (en) | 2005-12-28 | 2015-07-21 | Chugai Seiyaku Kabushiki Kaisha | Stabilized antibody-containing formulations |
| CA2638811A1 (en) | 2006-02-03 | 2007-08-16 | Medimmune, Llc | Protein formulations |
| DE102006005094A1 (de) | 2006-02-04 | 2007-08-09 | Degussa Gmbh | Titandioxid und Polycarboxylatether enthaltende Dispersion |
| ITMI20061030A1 (it) | 2006-05-26 | 2007-11-27 | Altergon Sa | Nuova composizione comprendente glicosamminoglicani a viscosita' controllata e uso di tale composizione nella terapuia della cistite cronica |
| CU23526B6 (es) | 2006-10-03 | 2010-05-19 | Ct Ingenieria Genetica Biotech | Método para la restauración morfofuncional de nervios periféricos en la neuropatía diabética |
| WO2008092084A2 (en) | 2007-01-26 | 2008-07-31 | Centocor, Inc. | Injectable non-aqueous suspension with high concentration of therapeutic agent |
| WO2008151022A2 (en) | 2007-05-31 | 2008-12-11 | Anterios, Inc. | Nucleic acid nanoparticles and uses therefor |
| WO2009015367A2 (en) | 2007-07-25 | 2009-01-29 | Arizona Board Of Regents For And On Behalf Of Arizona State University | Stabilizing proteins using ionic liquids |
| CA2696049A1 (en) | 2007-08-17 | 2009-02-26 | Amgen Inc. | Formulations of antibodies and fc-fusion molecules using polycations |
| EP2205280B1 (en) * | 2007-09-27 | 2019-09-04 | Amgen Inc. | Pharmaceutical formulations |
| ES2403413T3 (es) * | 2007-10-16 | 2013-05-17 | Pharmacyclics, Inc. | Manufactura, composiciones y usos del modulador del factor de coagulación Vlla |
| EP2219602A1 (en) | 2007-11-15 | 2010-08-25 | Amgen, Inc | Aqueous formulation of erythropoiesis stimulating protein stablised by antioxidants for parenteral administration |
| EP2234636A4 (en) | 2007-12-21 | 2013-05-15 | Lyotropic Therapeutics Inc | FORMULATIONS OF STABILIZED PEPTIDES AND PROTEINS |
| PE20091174A1 (es) | 2007-12-27 | 2009-08-03 | Chugai Pharmaceutical Co Ltd | Formulacion liquida con contenido de alta concentracion de anticuerpo |
| WO2009120684A1 (en) | 2008-03-25 | 2009-10-01 | Medimmune, Llc | Antibody formulation |
| US20110065675A1 (en) | 2008-05-05 | 2011-03-17 | University Of Miami | Azo dye related small molecule modulators of protein-protein interactions |
| EP2123307A1 (en) | 2008-05-20 | 2009-11-25 | Hexal Ag | Method for reducing leachables and extractables in syringes |
| EP2376522A4 (en) | 2008-11-16 | 2013-12-25 | Univ Texas | LOW VISCOSIS HIGHLY CONCENTRATED SUSPENSIONS |
| TWI342781B (en) | 2008-12-01 | 2011-06-01 | Univ China Medical | Blood sugar-modulating polypeptides |
| AR076640A1 (es) | 2009-03-06 | 2011-06-29 | Genentech Inc | Formulacion con anticuerpo. metodo para estabilizar anticuerpo. articulo de manufactura |
| WO2010132047A1 (en) | 2009-05-14 | 2010-11-18 | Rensselaer Polytechnic Institute | Guanosine/gmp gels and uses thereof |
| WO2010134345A1 (ja) | 2009-05-20 | 2010-11-25 | 積水メディカル株式会社 | 血液凝固時間延長剤 |
| EP2475376B1 (en) | 2009-06-17 | 2016-03-30 | BioMarin Pharmaceutical Inc. | Formulations for lysosomal enzymes |
| RU2012108108A (ru) | 2009-08-04 | 2013-09-10 | Дженентек, Инк. | Концентрированные полипептидные лекарственные формы с пониженной вязкостью |
| MX2012003282A (es) | 2009-09-17 | 2012-04-30 | Baxter Healthcare Sa | Co-formulacion estable de hialuronidasa e inmunoglobulina, y metodos de su uso. |
| EP2491123B1 (en) | 2009-10-20 | 2018-04-18 | The Regents of The University of California | Single molecule nucleic acid nanoparticles |
| UY32979A (es) | 2009-10-28 | 2011-02-28 | Abbott Lab | Inmunoglobulinas con dominio variable dual y usos de las mismas |
| AU2010320515B2 (en) | 2009-11-20 | 2013-05-02 | Biocon Limited | Formulations of antibody |
| WO2011069037A2 (en) | 2009-12-03 | 2011-06-09 | The University Of North Carolina At Charlotte | Stabilization and storage of biological pharmaceutical compositions |
| HUE041436T2 (hu) | 2009-12-10 | 2019-05-28 | Univ Minnesota | Tal-effektor-közvetített DNS-módosítás |
| ES2522935T3 (es) | 2010-01-08 | 2014-11-19 | Chanel Parfums Beauté | Uso de al menos un extracto de flores de Camellia japonica alba plena para hidratar la piel |
| DK2531218T3 (en) | 2010-02-04 | 2019-04-01 | Csl Behring Ag | immunoglobulin |
| BR112012021576A2 (pt) | 2010-02-26 | 2016-10-25 | Novo Nordisk As | composições estáveis contendo anticorpo. |
| US9956165B2 (en) | 2010-03-01 | 2018-05-01 | Cytodyn Inc. | Concentrated protein formulations and uses thereof |
| WO2011109415A2 (en) | 2010-03-02 | 2011-09-09 | Amgen Inc. | Reducing viscosity of pharmaceutical formulations |
| US9072668B2 (en) | 2010-03-09 | 2015-07-07 | Janssen Biotech, Inc. | Non-aqueous high concentration reduced viscosity suspension formulations of antibodies |
| PE20130203A1 (es) | 2010-03-17 | 2013-03-24 | Abbott Res Bv | Composiciones de anticuerpos anti-factor de crecimiento nervioso (ngf) |
| CA2794631A1 (en) | 2010-03-31 | 2011-10-06 | Universite De Geneve | Stabilized antibody preparations and uses thereof |
| CN101851267A (zh) | 2010-04-22 | 2010-10-06 | 江南大学 | 一种抗体保护剂及其应用 |
| KR20130060227A (ko) | 2010-05-03 | 2013-06-07 | 제넨테크, 인크. | 단백질-함유 제제의 점도 감소에 유용한 조성물 및 방법 |
| GB201012179D0 (en) | 2010-07-20 | 2010-09-01 | Future Injection Technologies | Injection device |
| US8936827B2 (en) * | 2011-02-25 | 2015-01-20 | Abbott Cardiovascular Systems Inc. | Methods of loading a hollow stent with a drug or drug formulation |
| US20140023655A1 (en) | 2011-04-07 | 2014-01-23 | Glaxosmithkline Llc | Formulations with reduced viscosity |
| CA2832560A1 (en) | 2011-04-07 | 2012-10-18 | Glaxosmithkline Llc | Formulations with reduced viscosity |
| JP6124873B2 (ja) * | 2011-05-12 | 2017-05-10 | バイエル・ヘルスケア・エルエルシーＢａｙｅｒ ＨｅａｌｔｈＣａｒｅ ＬＬＣ | 注入処置を制御するための様々なシステムを有する流体注入システム |
| RU2485133C2 (ru) | 2011-05-30 | 2013-06-20 | Закрытое Акционерное Общество "Фарм-Синтез" | Белково-полипептидный комплекс, обладающий тканеспецифическим регенеративно-репаративным и омолаживающим действием на кожную ткань, способ его получения и фармацевтическая композиция на его основе |
| US11707409B2 (en) | 2011-10-25 | 2023-07-25 | Corning Incorporated | Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients |
| AU2012328524B2 (en) | 2011-10-28 | 2017-05-18 | Excelse Bio, Inc. | Protein formulations containing amino acids |
| AR089434A1 (es) | 2011-12-23 | 2014-08-20 | Genentech Inc | Procedimiento para preparar formulaciones con alta concentracion de proteinas |
| US20140370012A1 (en) | 2012-01-27 | 2014-12-18 | Gliknik Inc. | Fusion proteins comprising igg2 hinge domains |
| CA2864539C (en) | 2012-02-16 | 2022-06-07 | Santarus, Inc. | Antibody formulations |
| US9574193B2 (en) * | 2012-05-17 | 2017-02-21 | Ionis Pharmaceuticals, Inc. | Methods and compositions for modulating apolipoprotein (a) expression |
| US20160002624A1 (en) * | 2012-05-17 | 2016-01-07 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide compositions |
| NZ701915A (en) | 2012-05-18 | 2016-11-25 | Genentech Inc | High-concentration monoclonal antibody formulations |
| EP3241902B1 (en) | 2012-05-25 | 2018-02-28 | The Regents of The University of California | Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription |
| EP2854760B1 (en) * | 2012-05-25 | 2018-10-17 | Novartis AG | Aqueous pharmaceutical composition containing a biologic therapeutic agent and l-arginine derivative and an injection including the composition |
| PE20150190A1 (es) | 2012-06-21 | 2015-02-13 | Ucb Pharma Sa | Formulacion farmaceutica |
| KR102530118B1 (ko) | 2012-07-25 | 2023-05-08 | 더 브로드 인스티튜트, 인코퍼레이티드 | 유도 ｄｎａ 결합 단백질 및 게놈 교란 도구 및 이의 적용 |
| EP2882775B1 (en) | 2012-08-09 | 2018-02-14 | Roche Glycart AG | Asgpr antibodies and uses thereof |
| FR2994390B1 (fr) | 2012-08-10 | 2014-08-15 | Adocia | Procede d'abaissement de la viscosite de solutions de proteines a concentration elevee |
| US9592297B2 (en) | 2012-08-31 | 2017-03-14 | Bayer Healthcare Llc | Antibody and protein formulations |
| FR2995214B1 (fr) | 2012-09-10 | 2014-11-21 | Adocia | Solution a viscosite reduite de proteine a concentration elevee |
| US10792044B2 (en) * | 2013-03-13 | 2020-10-06 | Applied Cardiovascular Solutions, LLC | Methods, compositions, and devices for the occlusion of cavities and passageways |
| US9669242B2 (en) | 2013-07-01 | 2017-06-06 | L'oreal | Compositions containing at least two phenolic compounds, a lipid-soluble antioxidant and at least one hydrotrope for cosmetic use |
| IL312865B2 (en) * | 2013-09-11 | 2025-06-01 | Eagle Biologics Inc | Liquid protein formulations containing viscosity-lowering agents |
| WO2015196091A1 (en) | 2014-06-20 | 2015-12-23 | Reform Biologics, Llc | Viscosity-reducing excipient compounds for protein formulations |
-
2015
- 2015-09-30 EP EP15845784.6A patent/EP3200804A4/en active Pending
- 2015-09-30 JP JP2017538156A patent/JP6716577B2/ja active Active
- 2015-09-30 SG SG10201902915VA patent/SG10201902915VA/en unknown
- 2015-09-30 MX MX2017004306A patent/MX391067B/es unknown
- 2015-09-30 KR KR1020177011967A patent/KR102497368B1/ko active Active
- 2015-09-30 AU AU2015325055A patent/AU2015325055B2/en active Active
- 2015-09-30 WO PCT/US2015/053313 patent/WO2016054259A1/en not_active Ceased
- 2015-09-30 CN CN201580064938.2A patent/CN106999510B/zh active Active
- 2015-09-30 SG SG11201702614SA patent/SG11201702614SA/en unknown
- 2015-09-30 US US15/516,074 patent/US11471479B2/en active Active
- 2015-09-30 CA CA2962768A patent/CA2962768C/en active Active
-
2017
- 2017-03-26 IL IL251390A patent/IL251390B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017530196A5 (https=) | ||
| JP2016534141A5 (https=) | ||
| JP2016530321A5 (ja) | イオン性液体を含有する注射用液状タンパク質製剤およびその使用 | |
| IL275388B2 (en) | Liquid protein formulations containing viscosity reducing agents | |
| JP2019073563A5 (https=) | ||
| JP2016530319A5 (https=) | ||
| JP2016530318A5 (https=) | ||
| RU2472487C2 (ru) | Гелевые полисахаридные композиции и способы длительной доставки лекарственных средств | |
| Zhang et al. | Delivery considerations of highly viscous polymeric fluids mimicking concentrated biopharmaceuticals: Assessment of injectability via measurement of total work done “WT” | |
| US11013683B2 (en) | Paliperidone implant formulation | |
| CN104689460B (zh) | 用于关节内粘弹性补充的方案 | |
| TWI789338B (zh) | 原位可交聯的多醣組合物之用途、關聯於其之多筒注射系統、用於形成原位可交聯的多醣組合物之衍生物之組合及用於形成原位可交聯的多醣組合物之套組 | |
| US11471479B2 (en) | Polysaccharide and nucleic acid formulations containing viscosity-lowering agents | |
| EP2866797B1 (en) | Stable injectable pharmaceutical composition of neurokinin 1 receptor antagonist and process for preparation thereof | |
| JP2015514751A5 (https=) | ||
| JP2016510329A5 (https=) | ||
| JP2019527729A5 (https=) | ||
| KR20060095974A (ko) | 트리암시놀론 아세토나이드 및 아네코르타브 아세테이트주사용 제제 | |
| CN105131348A (zh) | 一种无菌可注射材料 | |
| Patki et al. | Self-injectable extended release formulation of Remdesivir (SelfExRem): A potential formulation alternative for COVID-19 treatment | |
| US20230190783A1 (en) | Delivery of low viscosity formulations | |
| Meany et al. | Injectable polymer‐nanoparticle hydrogel for the sustained intravitreal delivery of bimatoprost | |
| CN102462680B (zh) | 噻吩诺啡的长效缓释微球及其组合物和制备方法 | |
| CN115282114B (zh) | 重组蛋白类药物可溶性微针配方及应用、微针及制备方法 | |
| CN104548278A (zh) | 一种依诺肝素钠封管注射液及其制备方法 |